Data from Hansa Medical’s First Phase II study of IdeS in Sensitized Kidney Transplantation Patients Presented in Oral Session at ESOT 2015
Swedish investigators presented data from the first completed phase II study of IdeS in sensitized patients at the 17thCongress of the European Society for Organ Transplantation (ESOT) in Brussels. Data from the Hansa Medical sponsored study show that IdeS can effectively reduce anti-HLA antibodies to levels acceptable for transplantation. The primary as well as secondary objectives of the study were reached and IdeS has an acceptable safety profile.“The data clearly support further development in transplantation and we are pleased that the investigators were given the opportunity to